E Fund Biopharma ETF(03186.HK) up 0.29%, ESMO data window nears
- As of 14:19 HKT on October 20, 2026, E Fund Biopharma ETF (03186.HK) rose 0.29% to HK$13.640.
- The ETF tracks the Solactive Biopharma Select Index, with assets of HK$28.4026 million and a board lot of 100 units.
NewTimeSpace News:As of 14:19 HKT on October 20, 2026, E Fund Biopharma ETF (03186.HK) traded at HK$13.640, up 0.29%, with turnover of HK$299,300 and a turnover rate of 1.05%.
NewTimeSpace has learned that E Fund Biopharma ETF (03186.HK) is managed by E Fund Asset Management (Hong Kong) and tracks the Solactive Biopharma Select Index, which covers Hong Kong-listed biopharma companies. As of 14:19 HKT on October 20, 2026, the ETF had assets of HK$28.4026 million, a net asset value of HK$13.525 per unit and a board lot of 100 units.
China's outbound licensing deals for innovative drugs have exceeded US$120 billion so far this year, up 36% year on year, with upfront payments topping US$10 billion.
Zhongtai Securities noted that the 2026 ESMO Congress will be held in Madrid from October 23 to 27, with 96 late-breaking abstracts (LBAs), 12 of which will be presented in presidential sessions; about 29 studies from China account for 30.2% of the total.
- E Fund Biopharma ETF(03186.HK) Rose 1.21% in the Morning Trading, with a Turnover Rate of 12.91%
- E Fund Biopharma ETF(03186.HK) rose 0.85% in the afternoon, with a trading volume of approximately HK$224,000
- E Fund Biopharma(03186.HK) up 1.47%, China out-licensing tops $120bn
- E Fund (HK) Solactive Biopharma Select Index ETF (03186.HK) Rises 2.24% to HKD 14.600
- E Fund (HK) Solactive Biopharma Select Index ETF (03186.HK) Rises 0.74%, NAV at HKD 14.978
